On July 28, 2026, Altimmune announced results from a clinical trial of its GLP-1 drug for alcohol-use disorder. The study found that the drug reduced heavy drinking among participants. The findings highlight a potential new application for GLP-1-based therapies in addiction medicine.
On July 28, 2026, Altimmune disclosed findings from a clinical trial evaluating its GLP-1 drug. The trial focused on alcohol-use disorder, a condition characterized by problematic alcohol consumption. The company reported that the drug reduced heavy drinking among study participants. Heavy drinking is a central symptom of alcohol-use disorder. The trial measured the drug's effect on this specific behavior. Altimmune's GLP-1 drug demonstrated a reduction in heavy drinking episodes.
The clinical trial enrolled individuals diagnosed with alcohol-use disorder. The primary outcome examined was the change in heavy drinking patterns. Heavy drinking involves consuming large quantities of alcohol over a short period. The study assessed how the GLP-1 drug influenced these episodes. Results showed that the drug led to a decrease in heavy drinking. This reduction is a key finding for the treatment of alcohol-use disorder.
Altimmune's drug belongs to the GLP-1 class of medications. GLP-1 receptor agonists are a category of therapeutic agents. In this trial, the drug was tested specifically for alcohol-use disorder. The drug showed an ability to reduce heavy drinking among participants. The trial's outcome indicates a potential role for GLP-1 drugs beyond their original indications.
The trial results were made public on July 28, 2026. Altimmune's GLP-1 drug reduced heavy drinking in the alcohol-use disorder trial. This finding adds to the growing body of research on GLP-1 drugs. The reduction in heavy drinking was a measured endpoint in the study. Altimmune has presented evidence that its GLP-1 drug can impact drinking behavior in a clinical setting.
On July 28, 2026, Altimmune reported that its GLP-1 drug reduced heavy drinking in a trial for alcohol-use disorder. The study demonstrates a potential new application for GLP-1 therapies. Altimmune's drug showed a positive effect on heavy drinking, a core symptom of alcohol-use disorder. The trial results provide data on the drug's effect in this patient population.
Peptides referenced: GLP-1.
Related reading: Danish weight-loss firm starts phase 2 study for obesity and diabetes, Potential Retatrutide Benefits Overview, Amylin Analog and Combination Therapy Trials Surge as Over 15 Companies Push Forward, Altimmune Reports Pemvidutide Reduces Drinking in Alcohol Use Disorder Trial.